

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EC Healthcare
醫思健康

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2138)

INSIDE INFORMATION
PROFIT WARNING

This announcement is made by EC Healthcare (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the latest assessment by the Board with reference to the preliminary unaudited consolidated management accounts of the Group for the year ended 31 March 2023 (the “**Reporting Period**”) currently available, it is expected that the financial results of the Group may record:

- (i) a decrease of not more than 61% in profit after tax (“**Net Profit**”) for the Reporting Period as compared with the Net Profit of approximately HK\$270.5 million for the corresponding period ended 31 March 2022; and
- (ii) a decrease of not more than 20% in earnings before interests, taxation, depreciation-owned property, plant and equipment and amortization (“**EBITDA**”) for the Reporting Period as compared with the EBITDA of approximately HK\$536.4 million for the corresponding period ended 31 March 2022.

The Board believes that such decrease in Net Profit and EBITDA during the Reporting Period was mainly attributable to (i) the capital expenditures expended on organic expansions of our new medical facilities which are yet to enter into service to generate income during the Reporting Period; (ii) the increase in operating costs due to inflationary pressure; and (iii) the increase in interest expenses.

The Board wishes to remind Shareholders and potential investors that the Company is still in the process of finalizing the final results of the Group for the Reporting Period and the operational data disclosed in this announcement is based on the unaudited management accounts of the Group, which have not yet been reviewed or audited by the auditors of the Company. The overall performance of the Group during the Reporting Period could be affected by a number of other factors and therefore, the operational data disclosed in this announcement for the Reporting Period may not reflect the overall performance of the Group for the same Reporting Period. Shareholders and potential investors are advised to read carefully the announcement of the Company in relation to the

consolidated results of the Group for the Reporting Period, which is expected to be released on or before 23 June 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EC Healthcare
Raymond Siu
Company Secretary

Hong Kong, 19 June 2023

As at the date of this announcement, the executive Directors of the Company are Mr. Tang Chi Fai, Mr. Lu Lyn Wade Leslie, Mr. Lee Heung Wing, Ms. Wong Ka Ki Ada, and Mr. Wong Chi Cheung; the non-executive Director is Mr. Luk Kun Shing Ben; and the independent non-executive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Au Tsun.